Current treatment options for metastatic castar-resistant prostate cancer
dc.contributor.author | Rozsypalová Aneta | cs |
dc.contributor.author | Dvořák Josef | cs |
dc.contributor.author | Richter Igor | cs |
dc.contributor.author | Buka D. | cs |
dc.contributor.author | Grimová Jana | cs |
dc.contributor.author | Matoušková Michaela | cs |
dc.date.accessioned | 2020-06-08T09:38:54Z | |
dc.date.available | 20-48-2019 | en |
dc.date.available | 2020-06-08T09:38:54Z | |
dc.date.issued | 2018-01-01 | cs |
dc.date.updated | 29-56-2019 | en |
dc.format.extent | 4 | cs |
dc.identifier.issn | 2464-7195 | cs |
dc.identifier.uri | https://dspace.tul.cz/handle/15240/155560 | |
dc.language.iso | cze | cs |
dc.publisher | Current Media s.r.o | cs |
dc.publisher.city | Praha | cs |
dc.relation.ispartof | Onkologická Revue | en |
dc.relation.ispartofseries | 1 | cs |
dc.subject | metastatic castration-resistant prostate cancer | cs |
dc.subject | docetaxel | cs |
dc.subject | cabazitaxel | cs |
dc.subject | abiraterone | cs |
dc.subject | enzalutamide | cs |
dc.subject | radium 223 | cs |
dc.title | Current treatment options for metastatic castar-resistant prostate cancer | en |
dc.title | Aktuální možnosti léčby metastazujícího kastračně rezistentního karcinomu prostaty | cs |
local.citation.epage | 1-4 | cs |
local.citation.spage | 1-4 | cs |
local.identifier.publikace | 6164 | |
local.relation.issue | 2 | cs |